Press release
Chronic Spontaneous Urticaria Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline Analysis | United BioPharma, Teva Pharmaceuticals Development, Inc., Amgen, N
Chronic Spontaneous Urticaria Pipeline Analysis
DelveInsight reports that over 20 leading companies are actively engaged in developing more than 20 treatment therapies for Chronic Spontaneous Urticaria.
Chronic Spontaneous Urticaria Overview:
Urticaria, commonly referred to as hives, wheals, or nettle rash-is marked by red, itchy, and swollen patches on the skin. Chronic Spontaneous Urticaria (CSU) is a subtype in which these hives occur almost daily and last for more than six weeks. It often involves widespread wheals and may include angioedema. Diagnosis typically relies on a clinical history of transient weals lasting less than 24 hours and without a known physical trigger. Current international guidelines suggest minimal diagnostic testing, focusing mainly on a complete blood count, erythrocyte sedimentation rate (ESR), and C-reactive protein (CRP) levels. Treatment options for CSU include antihistamines, omalizumab, cyclosporine, and low-dose corticosteroids.
Request for a detailed insights report on Chronic Spontaneous Urticaria pipeline insights @ https://www.delveinsight.com/report-store/chronic-spontaneous-urticaria-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr
"Chronic Spontaneous Urticaria Pipeline Insight 2025" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Chronic Spontaneous Urticaria Therapeutics Market.
Key Takeaways from the Chronic Spontaneous Urticaria Pipeline Report
*
DelveInsight's report on the Chronic Spontaneous Urticaria (CSU) pipeline highlights a dynamic landscape, with over 20 pharmaceutical companies actively developing more than 20 potential therapies for the condition. Leading players in this space include United BioPharma, Teva Pharmaceuticals, Amgen, Novartis, Allakos, Sanofi, Celltrion, Celldex Therapeutics, MICROBIO GROUP, Escient Pharmaceuticals, Jasper Therapeutics, Glenmark, Taiho Pharmaceuticals, ValenzaBio, Carna Biosciences, Servier, among others.
*
Several promising candidates are in various stages of development, such as Dupilumab, Tezepelumab, and Barzolvolimab. In November 2024, the FDA accepted a resubmission of the supplemental Biologics License Application (sBLA) for Dupixent to treat CSU in patients aged 12 and above who are not adequately managed by H1 antihistamines. The application is backed by positive Phase 3 LIBERTY-CUPID trial data, with a regulatory decision expected by April 18, 2025.
*
Meanwhile, Incyte discontinued patient enrollment in its CSU study of INCB000262 in November 2024 due to toxicology concerns found in lab tests, despite no adverse effects being observed in ongoing clinical trials. These findings were reported to the FDA and may influence future development.
*
In Europe, the EMA's Committee for Medicinal Products for Human Use recommended Omlyclo-a biosimilar of omalizumab-for approval in March 2024. It was granted marketing authorization in May 2024 for use in CSU, as well as in severe allergic asthma and chronic rhinosinusitis with nasal polyps.
*
Additionally, Novartis announced in November 2023 that its BTK inhibitor remibrutinib demonstrated statistically and clinically significant improvements in urticaria activity in a Phase III trial, reinforcing its potential as an effective oral therapy for CSU.
Chronic Spontaneous Urticaria Pipeline Analysis
The report provides insights into:
*
The report provides detailed insights into the key companies that are developing therapies in the Chronic Spontaneous Urticaria Market.
*
The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Chronic Spontaneous Urticaria treatment.
*
It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
*
It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
*
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Chronic Spontaneous Urticaria market.
Download our free sample page report on Chronic Spontaneous Urticaria pipeline insights [https://www.delveinsight.com/sample-request/chronic-spontaneous-urticaria-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Chronic Spontaneous Urticaria Emerging Drugs
*
Dupilumab: Sanofi
*
Tezepelumab: Amgen
*
Barzolvolimab: Celldex Therapeutics
Chronic Spontaneous Urticaria Companies
Over 20 prominent companies are actively working on therapies for Chronic Spontaneous Urticaria, with Sanofi leading the way-its drug candidate is the furthest along in development, currently in the preregistration stage.
DelveInsight's report covers around 20+ products under different phases of clinical development like
*
Late stage products (Phase III)
*
Mid-stage products (Phase II)
*
Early-stage product (Phase I) along with the details of
*
Pre-clinical and Discovery stage candidates
*
Discontinued & Inactive candidates
Chronic Spontaneous Urticaria pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
*
Intravenous
*
Subcutaneous
*
Oral
*
Intramuscular
Chronic Spontaneous Urticaria Products have been categorized under various Molecule types such as
*
Monoclonal antibody
*
Small molecule
*
Peptide
Download Sample Pages to Get an in-depth Assessment of the Emerging Chronic Spontaneous Urticaria Therapies and Key Companies: Chronic Spontaneous Urticaria Clinical Trials and advancements [https://www.delveinsight.com/report-store/chronic-spontaneous-urticaria-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Chronic Spontaneous Urticaria Pipeline Therapeutic Assessment
- Chronic Spontaneous Urticaria Assessment by Product Type
- Chronic Spontaneous Urticaria By Stage
- Chronic Spontaneous Urticaria Assessment by Route of Administration
- Chronic Spontaneous Urticaria Assessment by Molecule Type
Download Chronic Spontaneous Urticaria Sample report to know in detail about the Chronic Spontaneous Urticaria treatment market @ Chronic Spontaneous Urticaria Therapeutic Assessment [https://www.delveinsight.com/sample-request/chronic-spontaneous-urticaria-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Table of Content
1. Report Introduction
2. Executive Summary
3. Chronic Spontaneous Urticaria Current Treatment Patterns
4. Chronic Spontaneous Urticaria - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Chronic Spontaneous Urticaria Late-Stage Products (Phase-III)
7. Chronic Spontaneous Urticaria Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Chronic Spontaneous Urticaria Discontinued Products
13. Chronic Spontaneous Urticaria Product Profiles
14. Chronic Spontaneous Urticaria Key Companies
15. Chronic Spontaneous Urticaria Key Products
16. Dormant and Discontinued Products
17. Chronic Spontaneous Urticaria Unmet Needs
18. Chronic Spontaneous Urticaria Future Perspectives
19. Chronic Spontaneous Urticaria Analyst Review
20. Appendix
21. Report Methodology
Request the Sample PDF to Get Detailed Insights About the Chronic Spontaneous Urticaria Pipeline Reports Offerings [https://www.delveinsight.com/report-store/chronic-spontaneous-urticaria-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=chronic-spontaneous-urticaria-clinical-trials-companies-therapeutic-assessment-therapies-treatment-algorithm-pipeline-analysis-united-biopharma-teva-pharmaceuticals-development-inc-amgen-n]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Chronic Spontaneous Urticaria Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline Analysis | United BioPharma, Teva Pharmaceuticals Development, Inc., Amgen, N here
News-ID: 4134163 • Views: …
More Releases from ABNewswire
Bedrock Restoration - Water Fire Mold Damage Service, Expands Water Damage Repai …
Water Fire Mold Damage Service, a trusted provider of property restoration, has announced expanded service offerings to meet the growing demand for professional water damage solutions in the region. Known for their reliable, customer-focused approach, the company continues to support both homeowners and businesses in recovering from unexpected property damage caused by water, fire, or mold.
Responding to a Growing Need for Water Damage Restoration
Property owners across Minnesota are increasingly seeking…
Winkler Kurtz LLP Expands Resources to Handle Increased Demand for Personal Inju …
For individuals searching for personal injury attorneys, the expansion of Winkler Kurtz LLP's team means greater accessibility and reduced wait times for consultations. The firm's deep roots in the Port Jefferson Station community allow them to understand local nuances, such as common accident hotspots and specific regional legal precedents.
Port Jefferson Station has seen a notable rise in personal injury cases, driven by factors such as increased traffic congestion, construction activity,…
Protecting Property Value: Hose Bros Inc Highlights How Professional Power Washi …
For residents searching for power washing near me, Hose Bros Inc offers accessible and reliable services tailored to the Millsboro community. Their local expertise ensures an understanding of regional challenges, such as the impact of salt air on coastal properties or the tendency for humidity to promote mold growth in shaded areas. This knowledge allows them to customize their approach, selecting appropriate pressure levels and cleaning agents for different surfaces.
In…
![Tampa Bay Home Remodeling Costs Guide [2025] Kitchen & Bathroom Renovation Prices](https://cdn.open-pr.com/9/1/914818326_g.jpg)
Tampa Bay Home Remodeling Costs Guide [2025] Kitchen & Bathroom Renovation Price …
A 2025 cost guide to kitchen, bathroom, and full home remodeling in Tampa Bay, featuring expert insights from Craftline Remodeling on pricing, budgeting, and contractor selection.
Market Overview: Understanding Tampa Bay Remodeling Investment Trends
Tampa Bay's home remodeling market has experienced significant cost evolution in 2025, with project expenses varying dramatically across South Tampa, Carrollwood, Seminole Heights, Clearwater, St. Petersburg, and Wesley Chapel based on material choices, project scope, and contractor expertise.…
More Releases for Urticaria
Chronic Idiopathic Urticaria Market Insights and Future Outlook
Chronic idiopathic urticaria (CIU), also known as chronic spontaneous urticaria (CSU), is a persistent skin condition characterized by recurrent hives and itching lasting six weeks or longer without an identifiable trigger. While not life-threatening, the disease has a major impact on patients' quality of life due to discomfort, sleep disturbances, and psychological distress.
Conventional antihistamines and corticosteroids remain the mainstay of treatment, but biologics such as omalizumab (Xolair) and investigational therapies…
Chronic Spontaneous Urticaria (CSU) Market Massive Growth opportunity Ahead
Introduction
Chronic Spontaneous Urticaria (CSU) is a persistent skin condition characterized by recurrent itchy hives, swelling, and inflammation lasting for six weeks or longer without any identifiable external trigger. The disease severely impacts quality of life, with patients experiencing physical discomfort, sleep disturbances, and psychological stress.
Traditionally managed with antihistamines and corticosteroids, the treatment paradigm has shifted in recent years toward monoclonal antibodies, biologics, and novel immunomodulatory drugs. Rising awareness, increasing prevalence,…
Chronic Spontaneous Urticaria: A Leading Driver Behind Impact Of Increasing Alco …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
What Will the Chronic Spontaneous Urticaria Industry Market Size Be by 2025?
There has been a robust growth in the chronic spontaneous urticaria market in the past few years. It is projected to escalate from $2.06 billion in 2024 to $2.23 billion in 2025, rising at a compound annual…
Impact Of Increasing Alcohol Consumption On The Chronic Spontaneous Urticaria Ma …
The Chronic Spontaneous Urticaria Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Projected Growth of the Chronic Spontaneous Urticaria Market?
The chronic spontaneous urticaria market is expected to grow from $2.06 billion in 2024 to $2.23 billion in 2025, at a compound annual…
Chronic Urticaria Medicine Market Outlook and Future Projections for 2030
The chronic urticaria medicine market represents a dynamic and continually evolving landscape, shaped by changing consumer demands and technological advancements. In this comprehensive report, we provide an in-depth exploration of the market, designed for a wide range of stakeholders including manufacturers, suppliers, distributors, and investors. Our goal is to equip industry participants with essential insights that enable informed decision-making in an ever-changing market environment. This analysis not only examines the…
Chronic Spontaneous Urticaria Pipeline Therapeutics Assessment Report 2024 (Upda …
DelveInsight's, "Chronic Spontaneous Urticaria Pipeline Insight, 2024," report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Chronic Spontaneous Urticaria pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore our latest breakthroughs in Chronic Spontaneous Urticaria Research.…
